Payment overview · 2025
General Payments
$58.19
3 reported records · 3 companies
Healthcare provider profile · identity verified
Bert Eric Blackwell, D.O.
Allopathic & Osteopathic Physicians|Emergency Medicine|Undersea and Hyperbaric Medicine · TULSA, OK · NPI 1649221177
Verified facts
What the public records show
CMS Open Payments records show Bert Eric Blackwell, D.O. received $58.19 in general payments during 2025 across 3 reported records.
Dexcom, Inc. accounted for 41.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.12 | 41.5% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $20.47 | 35.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $13.60 | 23.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $58.19 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| 3M Cavilon Normalized: 3m cavilon |
Device | Solventum Corporation | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| KerraMax Care Normalized: kerramax care |
Device | Solventum Corporation | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| PROMOGRAN PRISMA Normalized: promogran prisma |
Device | Solventum Corporation | $20.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 1276 | 202 |
| Amlodipine Besylate | Amlodipine Besylate | 1010 | 171 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 969 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 857 | 184 |
| Jardiance | Empagliflozin | 813 | 142 |
| Metoprolol Succinate | Metoprolol Succinate | 715 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 695 | 109 |
| Ozempic | Semaglutide | 673 | 120 |
| Metformin Hcl | Metformin Hcl | 662 | 115 |
| Fluticasone Propionate | Fluticasone Propionate | 601 | 136 |
| Losartan Potassium | Losartan Potassium | 553 | 109 |
| Synthroid | Levothyroxine Sodium | 475 | 88 |
| Carvedilol | Carvedilol | 411 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 400 | 59 |
| Omeprazole | Omeprazole | 398 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 391 | 98 |
| Gabapentin | Gabapentin | 365 | 84 |
| Furosemide | Furosemide | 331 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 277 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 272 | 44 |
| Eliquis | Apixaban | 259 | 51 |
| Novolog Flexpen | Insulin Aspart | 243 | 48 |
| Celecoxib | Celecoxib | 228 | 38 |
| Droplet Pen Needle | Pen Needle, Diabetic | 222 | 41 |
| Sertraline Hcl | Sertraline Hcl | 219 | 44 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 212 | 43 |
| Tresiba Flextouch U-100 | Insulin Degludec | 198 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 38 |
| Allopurinol | Allopurinol | 187 | 27 |
| Atenolol | Atenolol | 187 | 25 |
| Alogliptin | Alogliptin Benzoate | 184 | 39 |
| Spiriva Respimat | Tiotropium Bromide | 165 | 34 |
| Finasteride | Finasteride | 156 | 19 |
| Montelukast Sodium | Montelukast Sodium | 154 | 42 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 151 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 60 |
| Trazodone Hcl | Trazodone Hcl | 147 | 32 |
| Meloxicam | Meloxicam | 146 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 142 | 43 |
| Potassium Chloride | Potassium Chloride | 128 | 39 |
| Oxybutynin Chloride | Oxybutynin Chloride | 121 | 25 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 15 |
| Torsemide | Torsemide | 105 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 101 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 15 |
| Terazosin Hcl | Terazosin Hcl | 94 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 94 | 19 |
| Ezetimibe | Ezetimibe | 89 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 20 |
| Levemir Flexpen | Insulin Detemir | 86 | 48 |
| Spironolactone | Spironolactone | 86 | 16 |
| Alendronate Sodium | Alendronate Sodium | 85 | 19 |
| Buspirone Hcl | Buspirone Hcl | 83 | 14 |
| Ibuprofen | Ibuprofen | 83 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 24 |
| Nitroglycerin | Nitroglycerin | 71 | 15 |
| Mirtazapine | Mirtazapine | 69 | 12 |
| Famotidine | Famotidine | 66 | 18 |
| Donepezil Hcl | Donepezil Hcl | 63 | 13 |
| Invokana | Canagliflozin | 58 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 56 | 14 |
| Lidocaine | Lidocaine | 53 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 52 | suppressed |
| Simvastatin | Simvastatin | 52 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | suppressed |
| Topiramate | Topiramate | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Glipizide Xl | Glipizide | 41 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 12 |
| Prednisone | Prednisone | 40 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | 13 |
| Glipizide Er | Glipizide | 30 | suppressed |
| Prevalite | Cholestyramine | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Naproxen | Naproxen | 25 | 12 |
| Ursodiol | Ursodiol | 25 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 17 |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 13 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Cephalexin | Cephalexin | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $58.19 · 3 records | Dexcom, Inc. | 3M Cavilon, Dexcom G6 Transmitter, KerraMax Care, PROMOGRAN PRISMA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error